A detailed history of Efg Capital International Corp. transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Efg Capital International Corp. holds 5,500 shares of BPMC stock, worth $516,285. This represents 0.08% of its overall portfolio holdings.

Number of Shares
5,500
Holding current value
$516,285
% of portfolio
0.08%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 02, 2023

BUY
$42.2 - $66.37 $232,100 - $365,035
5,500 New
5,500 $348 Million

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.61B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Efg Capital International Corp. Portfolio

Follow Efg Capital International Corp. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Efg Capital International Corp., based on Form 13F filings with the SEC.

News

Stay updated on Efg Capital International Corp. with notifications on news.